However, the rate of hospitalization due to heart failure wassignificantly lower in Group A (6.0%) than in Group B (10.6%) (p = 0.048), indicating a favorable effect of SGLT2 inhibitors on heartfailure prevention (Table 2 - see PDF). This evidence concerns the gene SLC5A2 and heart failure.